a Center for Dermatology Research, Department of Dermatology , Wake Forest School of Medicine , Winston-Salem , NC , USA.
b Department of Pathology , Wake Forest School of Medicine , Winston-Salem , NC , USA.
Expert Opin Pharmacother. 2019 Apr;20(5):621-629. doi: 10.1080/14656566.2018.1561868. Epub 2019 Jan 2.
Atopic dermatitis (AD) is one of the most common childhood skin disorders. Multiple mechanisms contribute to the pathology of AD and treatment approaches are directed at these processes.
The purpose of this review is to discuss the chemical treatment options for pediatric atopic dermatitis, including immunomodulators and small molecule inhibitors. A systematic literature search was conducted, and publications were reviewed for applicable treatment guidelines.
Topical therapy is first-line for pediatric atopic dermatitis. Providers should work closely with patients and caregivers to promote the success of topical treatments. In disease refractory to topical treatments, systemic agents may be considered. Clinical trials are ongoing for the use of biologics in the treatment of pediatric AD. When choosing the most appropriate treatment, physicians should consider the drug efficacy, potential adverse effects, patient adherence, and quality of life for both patients and caregivers. Additional studies are required to determine the safest and most effective doses for systemic therapy in childhood AD.
特应性皮炎(AD)是最常见的儿童皮肤疾病之一。多种机制导致 AD 的发病,治疗方法针对这些过程。
本综述旨在讨论儿科特应性皮炎的化学治疗选择,包括免疫调节剂和小分子抑制剂。进行了系统的文献检索,并对适用的治疗指南进行了出版物审查。
局部治疗是儿科特应性皮炎的一线治疗方法。医务人员应与患者和护理人员密切合作,以促进局部治疗的成功。对于局部治疗无效的疾病,可以考虑使用全身药物。目前正在进行生物制剂治疗儿科 AD 的临床试验。在选择最合适的治疗方法时,医生应考虑药物疗效、潜在不良反应、患者依从性以及患者和护理人员的生活质量。需要进一步研究以确定儿童 AD 全身治疗的最安全和最有效剂量。